202 related articles for article (PubMed ID: 37449450)
1. Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
Katsuragawa S; Goto A; Shinoda S; Inoue K; Nakai K; Saito J; Nishikawa T; Tsurutani Y
Hypertension; 2023 Sep; 80(9):1909-1920. PubMed ID: 37449450
[TBL] [Abstract][Full Text] [Related]
2. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study.
Brown JM; Robinson-Cohen C; Luque-Fernandez MA; Allison MA; Baudrand R; Ix JH; Kestenbaum B; de Boer IH; Vaidya A
Ann Intern Med; 2017 Nov; 167(9):630-641. PubMed ID: 29052707
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
4. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism.
Nomura M; Kurihara I; Itoh H; Ichijo T; Katabami T; Tsuiki M; Wada N; Yoneda T; Sone M; Oki K; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Inagaki N; Yamamoto K; Otsuki M; Yabe D; Izawa S; Takahashi Y; Suzuki T; Yasoda A; Tanabe A; Naruse M;
Hypertens Res; 2022 Sep; 45(9):1476-1485. PubMed ID: 35764671
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Tezuka Y; Turcu AF
Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
[TBL] [Abstract][Full Text] [Related]
6. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
7. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
[TBL] [Abstract][Full Text] [Related]
8. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
9. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):51-59. PubMed ID: 29129576
[TBL] [Abstract][Full Text] [Related]
10. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension.
Mansur A; Vaidya A; Turchin A
Am J Hypertens; 2023 Jul; 36(8):455-461. PubMed ID: 37013957
[TBL] [Abstract][Full Text] [Related]
11. Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function.
Kobayashi H; Abe M; Nakamura Y; Takahashi K; Fujita M; Takeda Y; Yoneda T; Kurihara I; Itoh H; Tsuiki M; Wada N; Ichijo T; Katabami T; Ogawa Y; Kawashima J; Yoshimoto T; Sone M; Inagaki N; Watanabe M; Kamemura K; Matsuda Y; Izawa S; Tanabe M; Tanabe A; Suzuki T; Naruse M;
Hypertension; 2019 Sep; 74(3):630-638. PubMed ID: 31327258
[TBL] [Abstract][Full Text] [Related]
12. Continuum of Renin-Independent Aldosteronism in Normotension.
Baudrand R; Guarda FJ; Fardella C; Hundemer G; Brown J; Williams G; Vaidya A
Hypertension; 2017 May; 69(5):950-956. PubMed ID: 28289182
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y; Turcu AF
Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
Nakano Y; Murakami M; Hara K; Fukuda T; Horino M; Takeuchi A; Niitsu Y; Shiba K; Tsujimoto K; Komiya C; Yokoyama M; Ikeda K; Yoshimoto T; Fujii Y; Yamada T
Clin Endocrinol (Oxf); 2023 Mar; 98(3):323-331. PubMed ID: 36367014
[TBL] [Abstract][Full Text] [Related]
17. Implication of MR Activity in Posttreatment Arterial Stiffness Reversal in Patients With Primary Aldosteronism.
Chen ZW; Pan CT; Liao CW; Tsai CH; Chang YY; Chang CC; Lee BC; Chiu YW; Huang WC; Wang SM; Lu CC; Chueh JS; Wu VC; Hung CS; Lin YH
J Clin Endocrinol Metab; 2023 Feb; 108(3):624-632. PubMed ID: 36333943
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
19. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study.
Brown JM; Wijkman MO; Claggett BL; Shah AM; Ballantyne CM; Coresh J; Grams ME; Wang Z; Yu B; Boerwinkle E; Vaidya A; Solomon SD
Hypertension; 2022 Sep; 79(9):1984-1993. PubMed ID: 35582954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
